Targeting the MAPK Pathway in KRAS-Driven Tumors.

doi:10.1016/j.ccell.2020.03.013

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Targeting the MAPK Pathway in KRAS-Driven Tumors.

Cancer cell - 13 Apr 2020

Drosten Matthias, Barbacid Mariano

Abstract excerpt

KRAS mutations occur in a quarter of all of human cancers, yet no selective drug has been approved to treat these tumors. Despite the recent development of drugs that block KRASG12C, the majority of KRAS oncoproteins remain undruggable. Here, we review recent efforts to validate individual components of the mitogen-activated protein kinase (MAPK) pathway as targets to treat KRAS-mutant cancers by comparing...

Topics

Humans
Mitogen-Activated Protein Kinases
Molecular Targeted Therapy
Mutation
Neoplasms
Protein Kinase Inhibitors
Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 32289276
DOI: 10.1016/j.ccell.2020.03.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics